Regeneron CEO Schleifer, a year after public Pfizer spat, slams Allergan for tribal deal
admin 1st December 2017 Uncategorised 0In Congress, on social media and elsewhere, Allergan and its CEO Brent Saunders have taken plenty of heat about the company’s controversial tribal patent transfer to protect intellectual property for blockbuster eye medication Restasis. But this week, the drugmaker found a new source of criticism.
More: Regeneron CEO Schleifer, a year after public Pfizer spat, slams Allergan for tribal deal
Source: fierce